Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052

被引：0

作者：

Spencer, Andrew ^{[1
]}

Millward, Michael ^{[2
,3
]}

Mainwaring, Paul ^{[4
]}

Harrison, Simon ^{[5
]}

Catley, Laurence ^{[6
]}

Townsend, Amanda ^{[7
]}

Sukumaran, Shawgi ^{[7
]}

Longenecker, Angie M. ^{[8
]}

Palladino, Michael A. ^{[8
]}

Lloyd, G. Kenneth ^{[8
]}

Neuteboom, Saskia ^{[8
]}

Padrik, Peeter ^{[9
]}

Spear, Matthew A. ^{[8
]}

Price, Timothy ^{[7
]}

机构：

[1] Alfred Hosp, Melbourne, Vic, Australia

[2] Sir Charles Gairdner Hosp, Perth, WA 6000, Australia

[3] Univ Western Australia, Perth, WA 6009, Australia

[4] Mater Hosp, Brisbane, Qld, Australia

[5] Peter MacCallum Canc Inst, Dept Hematol, Melbourne, Vic 3000, Australia

[6] Mater Adult Hosp, Canc Serv, Brisbane, Qld, Australia

[7] Queen Elizabeth Hosp, Adelaide, SA, Australia

[8] Nereus Pharmaceut Inc, San Diego, CA USA

[9] Tartu Univ Hosp, Tartu, Estonia

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1053 / 1054

页数：2

共 50 条

[31] The proteasome inhibitor NPI-0052 in combination with bortezomib induces antitumor activity in Waldenstrom macroglobulinemia.
Jia, Xiaoying
Leleu, Xavier
Moreau, Anne-Sophie
Hatjiharisi, Evdoxia
Ngo, Hai
O'Sullivan, Garrett
McMillin, Douglas
Treon, Steven
Mitsiades, Constantine
Hideshima, Teru
Palladino, Michael
Anderson, Kenneth
Chauban, Dharminder
Ghobrial, Irene
BLOOD, 2006, 108 (11) : 270B - 270B
[32] Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization
Baritaki, Stavroula
Yeung, Kam
Palladino, Michael
Berenson, James
Bonavida, Benjamin
CANCER RESEARCH, 2009, 69 (21) : 8376 - 8385
[33] Proteasome inhibitor NPI-0052 appears more effective than bortezomib in treatment of leukemia in animal models
不详
CANCER BIOLOGY & THERAPY, 2007, 6 (05) : 629 - 630
[34] Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results
Harrison, Simon J.
Mainwaring, Paul
Price, Timothy
Millward, Michael J.
Padrik, Peeter
Underhill, Craig R.
Cannell, Paul K.
Reich, Steven D.
Trikha, Mohit
Spencer, Andrew
CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4559 - 4566
[35] The novel, orally active proteasome inhibitor, NPI-0052, induces apoptosis in leukemia lymphoma cell lines and patient specimens.
Miller, CP
Ban, K
Ruiz, SL
Neuteboom, S
Palladino, M
McConkey, D
Chandra, J
BLOOD, 2005, 106 (11) : 74A - 74A
[36] THE PROTEASOME INHIBITOR NPI-0052 TARGETS GLIOMA STEM CELLS AND RADIOSENSITIZES GLIOBLASTOMAS IN-VITRO AND IN-VIVO
Mattes, M.
Vlashi, E.
Della Donna, L.
Lagadec, C.
McDonald, T.
Pajonk, F.
JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (01) : 120 - 120
[37] Caspase-8 and oxidant dependent hyper-acetylation of histone-H3 by the novel proteasome inhibitor NPI-0052
Miller, Claudia
Rudra, Sharmistha
Keating, Michael
Wierda, William
Palladino, Michael
Chandra, Joya
CANCER RESEARCH, 2009, 69
[38] Stabilization Effect of Resin on the Production of Potent Proteasome Inhibitor NPI-0052 During Submerged Fermentation of Salinispora tropica
Ginger Tsueng
Kin S Lam
The Journal of Antibiotics, 2007, 60 : 469 - 472
[39] Stabilization effect of resin on the production of potent proteasome inhibitor NPI-0052 during submerged fermentation of Salinispora tropica
Tsueng, Ginger
Lam, Kin S.
JOURNAL OF ANTIBIOTICS, 2007, 60 (07): : 469 - 472
[40] A novel orally available proteasome inhibitor NPI-0052 induces killing in multiple myeloma (MM) cells resistant to conventional and bortezomib therapies
Chauhan, D
Li, GL
Podar, K
Hideshima, T
Shrigarpure, R
Catley, L
Mitsiades, C
Munshi, N
Sclossman, R
Bahjat, R
Neuteboom, S
Richardson, P
Palladino, M
Anderson, KC
BLOOD, 2004, 104 (11) : 661A - 661A

← 1 2 3 4 5 →